Skip subpage navigation
Nov. 7-8, 2018
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Aug. 07, 2018
- Pre-Proposal Teleconference: Aug. 20, 2018 @ 1:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: August - September 2018
- UF BPA & UF ADP Quotes Due: Sept. 28, 2018
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- NEUROLOGICAL AGENTS MISCELLANEOUS - MOVEMENT DISORDERS:
- Austedo
- Ingrezza
- Xenazine
- GASTROINTESTINAL-2 AGENTS - MISCELLANEOUS:
- Alinia
- Dificid
- Lotronex
- Viberzi
- Xifaxan
- GASTROINTESTINAL-2 AGENTS - CIC AND IBS-C:
|
|
|
Aug. 8-9, 2018
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: May 1, 2018
- Pre-Proposal Teleconference: May 14, 2018 @ 1:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: May - June 2018
- UF BPA & UF ADP Quotes Due: June 22, 2018
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- CORTICOSTEROIDS-IMMUNE MODULATORS- ATOPIC DERMATITIS:
- Dupixent
- Elidel
- Eucrisa
- Protopic
- HEPATITIS C AGENTS - DIRECT ACTING AGENTS:
- Daklinza
- Epclusa
- Harvoni
- Mavyret
- Olysio
- Sovaldi
- Viekira XR
- Viekira Pak
- Vosevi
- Zepatier
|
-
Aimovig
-
Balcoltra
-
Braftovi
-
Doptelet
-
Imvexxy
-
Jynarque
-
Lucemyra
-
Mektovi
-
Olumiant
-
Osmolex ER
-
Palynziq
-
Retacrit
-
Roxybond
-
Siklos
-
Tavalisse
-
Yonsa
|
|
May 9-10, 2018
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Feb. 6, 2018
- Pre-Proposal Teleconference: February 14, 2018 @ 12:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: February - March 2018
- UF BPA & UF ADP Quotes Due: March 30, 2018
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- GASTROINTESTINAL-2 AGENTS - OPIOID INDUCED CONSTIPATION:
- Movantik
- Relistor
- Symprioc
- GROWTH STIMULATING AGENTS:
- Genotropin
- Humatrope
- Humatropen
- Norditropin Flexpro
- Nutropin AQ
- Nutropin AQ Nuspin
- Omnitrope
- Saizen
- Saizen-SaizenPrep
- Serostim
- Zomacton
- Zorbtive
- PANCREATIC ENZYME AGENTS:
- Creon
- Pancreaze
- Pertzye
- Ultresa
- Viokace
- Zenpep
|
- Admelog
- Adzenys ER
- Biktarvy
- Bonjesta
- Cimduo
- Erleada
- Firvanq
- Imbruvica
- Impoyz
- Lonhala Magnair
- Noctiva
- Rhopressa
- Segluromet
- Solosec
- Steglatro
- Steglujan
- Symdeko
- Symfi
- Symfi Lo
- Zypitamag
|
|
Feb. 7-8, 2018
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Nov. 3, 2017
- Pre-Proposal Teleconference: Nov. 9, 2017 @ 12:00 p.m. Central
- Clinical/Cost Presentation Meeting Window: November - December 2017
- UF BPA & UF ADP Quotes Due: Jan. 5, 2018
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- Anti-inflammatory Immunomodulatory Ophthalmic Agents - Opthalmic Immunomodulatory Agents:
- Restasis
- Restasis Multidose
- Xiidra
- Diabetes Non-Insulin - Glucagon-like Peptide-1 (GLP-1) Receptor Agonists:
- Adlyxin
- Byetta
- Ozempic
- Trulicity
- Victoza
- Osteoporosis Agents - PTH Analogues:
- Corticosteroids-Immune Modulators - Adrenocorticotropic Hormomes:
|
- Benznidazole
- Calquence
- Carospir
- Clenpiq
- Hemlibra
- Juluca
- Odactra
- Prevymis
- Qtern
- Rebinyn
- Vyzulta
- Xhance
- Ximino
|
|
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: April 25, 2024